Pharming Group NV (PHAR) — Capital Reinvestment Ratio
Latest as of March 2026:
0.15x
Pharming Group NV (PHAR) has a Capital Reinvestment Ratio of 0.15x as of March 2026, meaning it reinvests 0% of its operating cash flow ($1.63 Million) in capital expenditures ($238.86K). See PHAR free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.15x
Capex / Operating Cash Flow
Operating Cash Flow
$1.63 Million
USD
Capital Expenditures
$238.86K
USD
Data as of
Mar 2026
Most recent filing
Pharming Group NV Capital Reinvestment Ratio (2017–2025)
This chart tracks Pharming Group NV's Capital Reinvestment Ratio across 7 annual periods.
Annual Capital Reinvestment Ratio for Pharming Group NV (2017–2025)
Year-by-year Capital Reinvestment Ratio for Pharming Group NV from 2017 to 2025. For live market cap and broader valuation context, see Pharming Group NV stock valuation.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.02x | $50.07 Million | $751.09K | ▼ -83.0% |
| 2022 | 0.09x | $22.46 Million | $1.98 Million | ▼ -80.1% |
| 2021 | 0.44x | $37.84 Million | $16.72 Million | ▲ +141.4% |
| 2020 | 0.18x | $83.63 Million | $15.30 Million | ▼ -46.7% |
| 2019 | 0.34x | $74.15 Million | $25.45 Million | ▲ +267.7% |
| 2018 | 0.09x | $46.19 Million | $4.31 Million | ▼ -41.0% |
| 2017 | 0.16x | $45.84 Million | $7.25 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow